A Randomized, Double-Blind Study to Investigate the Effect of aleglitazar [R1439] on Glycemic Control in Patients With Type 2 Diabetes Mellitus.

Trial Profile

A Randomized, Double-Blind Study to Investigate the Effect of aleglitazar [R1439] on Glycemic Control in Patients With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Aleglitazar (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms SYNCHRONY
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Aug 2010 Pharmacodynamic outcomes were reported at the ESC Congress 2010: Annual Congress of the European Society of Cardiology.
    • 14 Nov 2009 Results of an exploratory analysis on the effects of aleglitazar on cardiovascular markers has been published as an abstract in the proceedings from the 82nd Annual Scientific Sessions of the American Heart Association (AHA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top